PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21986835-5	2011	Four days after intravenous cefepime initiation, the patient developed thrombocytopenia with platelet count dropping from 102 x 10(3)/muL to 15 x 10(3)/muL.	Cefepime	28-36	tripartite motif containing 37	Homo sapiens	134-137
22960890-14	2012	Cefepime was the best cephalosporin in synergy with tazobactam for detecting ESBL production in isolates co-producing AmpC beta-lactamases.	Cefepime	0-8	beta-lactamase	Klebsiella pneumoniae	118-122
22298349-0	2012	Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports.	Cefepime	28-36	colony stimulating factor 2	Homo sapiens	10-13
22290945-10	2012	Cefepime was less active, with only 74.2% being susceptible due to the predominance of CTX-M-15.	Cefepime	0-8	hypothetical protein	Escherichia coli	87-95
22005996-3	2012	Cefepime is a cephalosporin whose 3" side chain provides some stability against AmpC beta-lactamases.	Cefepime	0-8	beta-lactamase	Pseudomonas aeruginosa PAO1	80-84
22005996-4	2012	We examined the activity of cefepime against P. aeruginosa wild-type strain PAO1 and its isogenic AmpC stably derepressed mutant in our hollow-fiber infection model.	Cefepime	28-36	beta-lactamase	Pseudomonas aeruginosa PAO1	98-102
22960890-18	2012	Amongst cephalosporins, cefepime was the best cephalosporin in detecting ESBL in presence of AmpC beta-lactamase as it is least hydrolyzed by AmpC enzymes.	Cefepime	24-32	beta-lactamase	Klebsiella pneumoniae	93-97
22960890-18	2012	Amongst cephalosporins, cefepime was the best cephalosporin in detecting ESBL in presence of AmpC beta-lactamase as it is least hydrolyzed by AmpC enzymes.	Cefepime	24-32	beta-lactamase	Klebsiella pneumoniae	142-146
22960890-19	2012	Cefepime-tazobactam combination disk test would be a simple and best method in detection of ESBLs in Enterobacteriaceae co-producing AmpC beta-lactamase in the routine diagnostic microbiology laboratories.	Cefepime	0-8	beta-lactamase	Klebsiella pneumoniae	133-137
22345386-7	2012	As for ESBL-producing ENSE isolates, 25% and 14.3% of E. coli isolates and 36.5% and 10.8% of K. pneumoniae isolates were susceptible to cefepime based on CLSI and EUCAST criteria, respectively.	Cefepime	137-145	EsbL	Escherichia coli	7-11
22041508-8	2012	In conclusion, combinations of imipenem, cefepime and ceftazidime with avibactam may present a promising therapeutic strategy to treat infections due to K. pneumoniae with OXA-48 enzyme as well as K. pneumoniae and E. coli with CTX-M-15 enzyme.	Cefepime	41-49	OXA-48	Klebsiella pneumoniae	172-178
21986835-5	2011	Four days after intravenous cefepime initiation, the patient developed thrombocytopenia with platelet count dropping from 102 x 10(3)/muL to 15 x 10(3)/muL.	Cefepime	28-36	tripartite motif containing 37	Homo sapiens	152-155
21986835-6	2011	Cefepime was discontinued and the platelet count normalized to 140 x 10(3)/muL after 6 days.	Cefepime	0-8	tripartite motif containing 37	Homo sapiens	75-78
21767713-1	2011	Salmonella enterica (S. Typhimurium) strains from Kenya, Malawi, and Ireland showing elevated cefepime MIC values carried bla(OXA-1).	Cefepime	94-102	Bla	Salmonella enterica subsp. enterica serovar Typhimurium	122-125
26592057-4	2011	This study was done to determine in vitro activity of cefepime against ESBL producing clinical isolates.	Cefepime	54-62	EsbL	Escherichia coli	71-75
26592057-8	2011	Cefepime is less active against ESBL producing organisms; hence the use.of this drug should be guided using local resistance profile.	Cefepime	0-8	EsbL	Escherichia coli	32-36
21742679-15	2011	CONCLUSIONS: The "cefpiromase" or "cefepimase" ESBL phenotype of the clinical isolates non-susceptible to cefpirome and cefepime resulted from high expression of TEM-1 or OXA-1 beta-lactamases combined with loss of porins.	Cefepime	120-128	hypothetical protein	Escherichia coli	162-167
21742679-15	2011	CONCLUSIONS: The "cefpiromase" or "cefepimase" ESBL phenotype of the clinical isolates non-susceptible to cefpirome and cefepime resulted from high expression of TEM-1 or OXA-1 beta-lactamases combined with loss of porins.	Cefepime	120-128	beta-lactamase OXA-1 precursor	Escherichia coli	171-176
21393128-3	2011	After adjusting for the propensity to receive cefepime, multivariable Cox proportional hazard regression was used to compare the 28 day mortality in patients who were treated with cefepime with that in those who received other beta-lactam antibiotics.	Cefepime	180-188	cytochrome c oxidase subunit 8A	Homo sapiens	70-73
21149619-1	2011	Constitutive overexpression of the active efflux system MexXY/OprM is a major cause of resistance to aminoglycosides, fluoroquinolones, and cefepime in clinical strains of Pseudomonas aeruginosa.	Cefepime	140-148	outer membrane protein OprM	Pseudomonas aeruginosa PAO1	62-66
20130375-7	2009	The cefepime/cefepime-clavulanate Etest strip detected the maximum number of isolates (70/113, 61.9 %) as ESBL-positive compared to the ceftazidime/ceftazidime-clavulanate and cefotaxime/cefotaxime-clavulanate strips, which detected 57 (50.4%) isolates each as ESBL-positive.	Cefepime	4-12	EsbL	Escherichia coli	261-265
20194701-11	2010	The cefepime resistance conferred by ISAba1-bla(OXA-23) and the impact of ISAba1-bla(OXA-66) on carbapenem resistance in A. baumannii are reported here for the first time.	Cefepime	4-12	class D beta-lactamase OXA-23	Acinetobacter baumannii	48-54
20130375-7	2009	The cefepime/cefepime-clavulanate Etest strip detected the maximum number of isolates (70/113, 61.9 %) as ESBL-positive compared to the ceftazidime/ceftazidime-clavulanate and cefotaxime/cefotaxime-clavulanate strips, which detected 57 (50.4%) isolates each as ESBL-positive.	Cefepime	4-12	EsbL	Escherichia coli	106-110
20130375-9	2009	In the 66 (58.4%) isolates that co-produced AmpC in addition to the ESBL enzymes, cefepime/cefepime-clavulanate Etest strip detected ESBL in an additional 13 (11.4%) isolates as compared to the other ESBL Etest strips.	Cefepime	82-90	beta-lactamase	Escherichia coli	44-48
18658192-7	2008	RESULTS: Sustained bacterial killing was achieved by cefepime at lower drug concentrations in CSF(CO(2)) than in MHB.	Cefepime	53-61	complement C2	Homo sapiens	94-104
20130375-9	2009	In the 66 (58.4%) isolates that co-produced AmpC in addition to the ESBL enzymes, cefepime/cefepime-clavulanate Etest strip detected ESBL in an additional 13 (11.4%) isolates as compared to the other ESBL Etest strips.	Cefepime	82-90	EsbL	Escherichia coli	133-137
20130375-9	2009	In the 66 (58.4%) isolates that co-produced AmpC in addition to the ESBL enzymes, cefepime/cefepime-clavulanate Etest strip detected ESBL in an additional 13 (11.4%) isolates as compared to the other ESBL Etest strips.	Cefepime	82-90	EsbL	Escherichia coli	133-137
19414578-0	2009	Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.	Cefepime	26-34	CMY-2 beta-lactamase	Escherichia coli	104-124
18772158-8	2008	Although the isolate did not produce an AmpC-type enzyme, the production of KPC-2 was associated with positive boronic acid disc tests using cephamycins and cefotaxime as well as cefepime and carbapenems as substrates.	Cefepime	179-187	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	76-81
18519727-8	2008	By contrast, there was a lower level of restoration of susceptibility of MRSA ATCC 33591 to cefuroxime and cefepime after phagocytosis by THP-1 macrophages, even when the data were normalized for differences in MICs.	Cefepime	107-115	GLI family zinc finger 2	Homo sapiens	138-143
18781908-2	2008	The objective of present study was to evaluate effect of fixed dose combination of cefepime + amikacin on antioxidant enzymes such as superoxide dismutase (SOD), catalase along with malonaldialdehyde (MDA) levels in liver of Mus musculus mice.	Cefepime	83-91	catalase	Mus musculus	162-170
18781908-4	2008	A significant improvement in the activities of superoxide dismutase and catalase along with decrease in MDA levels were observed in fixed dose combination of cefepime plus amikacin treated groups as compared to amikacin alone treated group.	Cefepime	158-166	catalase	Mus musculus	72-80
18559652-3	2008	A homology model suggests that the VIM-7 Tyr-218 Phe substitution may be responsible for the reduced catalytic efficiency against certain cephalosporins, including ceftazidime and cefepime.	Cefepime	180-188	vimentin	Homo sapiens	35-38
16930923-12	2007	Cefepime was also the most active beta-lactam agent tested against Enterobacter spp.	Cefepime	0-8	histocompatibility minor 13	Homo sapiens	80-83
18567754-11	2008	Relative to d 10, enhanced expression of OCTN2 and ATB(0,+) in mammary glands at d 4 of lactation and higher M/S (L-carnitine and cefepime) suggests cefepime competes with L-carnitine for L-carnitine transporters expressed in the lactating mammary gland to adversely affect L-carnitine milk concentrations and these effects depend upon lactation stage.	Cefepime	149-157	solute carrier family 22 member 5	Rattus norvegicus	41-46
16930925-0	2007	Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.	Cefepime	57-65	outer membrane protein OprM	Pseudomonas aeruginosa PAO1	118-122
18452417-11	2008	Cefepime plasma concentrations can be predicted based on BSA and calculated CL(CR).	Cefepime	0-8	chymotrypsin C	Homo sapiens	76-82
18294108-0	2008	In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.	Cefepime	21-29	CTX-M-15	Klebsiella pneumoniae	104-136
18294108-1	2008	STUDY OBJECTIVE: To evaluate the activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli.	Cefepime	45-53	CTX-M-15	Klebsiella pneumoniae	128-160
17084784-0	2006	Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.	Cefepime	7-15	beta-lactamase	Klebsiella pneumoniae	76-90
17084784-1	2006	An investigation to determine the efficacy of cefepime in treating infections caused by extended spectrum beta-lactamase (ESBL)-producing strains of Klebsiella pneumonia and Escherichia coli was performed.	Cefepime	46-54	beta-lactamase	Klebsiella pneumoniae	106-120
17084784-1	2006	An investigation to determine the efficacy of cefepime in treating infections caused by extended spectrum beta-lactamase (ESBL)-producing strains of Klebsiella pneumonia and Escherichia coli was performed.	Cefepime	46-54	EsbL	Escherichia coli	122-126
17084784-5	2006	Cefepime is a potential alternative, in many cases, to the carbapenems for the treatment of infections caused by ESBL-producing bacteria.	Cefepime	0-8	EsbL	Escherichia coli	113-117
16544267-4	2006	Effective strategies for the empirical and directed treatment of infections caused by ESBL-producing pathogens include the use of carbapenems and, possibly, the fourth-generation cephalosporin cefepime.	Cefepime	193-201	EsbL	Escherichia coli	86-90
16440125-8	2006	A cefepime MIC < or = 8 mg/L was found in 77.5% of ESBL-EC and 73.3% of ESBL-KP isolates.	Cefepime	2-10	EsbL	Escherichia coli	54-58
16544267-6	2006	The probability of attaining time above the minimum inhibitory concentration targets of at least 70% of the dosing interval, an important pharmacodynamic indicator of clinical success, is higher with cefepime than with other antimicrobials against Escherichia coli and Klebsiella pneumoniae strains exhibiting ESBL phenotypes.	Cefepime	200-208	EsbL	Escherichia coli	310-314
16544267-8	2006	When used appropriately in institutional settings, cefepime reduces the overall use of cephalosporins, thereby decreasing selection pressure for presumptive ESBL-producing pathogens.	Cefepime	51-59	EsbL	Escherichia coli	157-161
16440125-8	2006	A cefepime MIC < or = 8 mg/L was found in 77.5% of ESBL-EC and 73.3% of ESBL-KP isolates.	Cefepime	2-10	EsbL	Escherichia coli	75-79
16230218-0	2005	Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.	Cefepime	118-126	EsbL	Escherichia coli	59-63
16290025-21	2006	with ESBL phenotypes were likely to harbor CMY-2 (not an ESBL) and remain susceptible to cefepime, carbapenems, and fluoroquinolones, which can be used for serious invasive Salmonella spp.	Cefepime	89-97	histocompatibility minor 13	Homo sapiens	184-187
16230218-1	2005	OBJECTIVE: To determine the affect of ESBL production among Klebsiella species and Escherichia coli on cefepime effectiveness.	Cefepime	103-111	EsbL	Escherichia coli	38-42
16230218-2	2005	METHODS: This was a retrospective, case-controlled study comparing the clinical and microbiologic responses of patients receiving cefepime for ESBL producing Klebsiella species or E. coli from a non-urine source with matched controls receiving cefepime for non-ESBL strains.	Cefepime	130-138	EsbL	Escherichia coli	143-147
16230218-2	2005	METHODS: This was a retrospective, case-controlled study comparing the clinical and microbiologic responses of patients receiving cefepime for ESBL producing Klebsiella species or E. coli from a non-urine source with matched controls receiving cefepime for non-ESBL strains.	Cefepime	130-138	EsbL	Escherichia coli	261-265
16230218-9	2005	CONCLUSION: These data indicate that ESBL production among non-urinary Klebsiella species and E. coli negatively affected cefepime effectiveness.	Cefepime	122-130	EsbL	Escherichia coli	37-41
15728940-1	2005	We applied in vitro evolution to an Escherichia coli strain containing bla(CTX-M-2) and obtained 10 independent mutant bla(CTX-M-2) alleles that confer elevated resistance to ceftazidime (MIC > or = 32 microg/ml) but lost the ability to confer resistance to cefepime.	Cefepime	261-269	beta-lactamase	Escherichia coli	119-122
12702671-2	2003	To determine whether the TEM beta-lactamases have the potential to evolve cefepime resistance, we evolved the ancestral TEM allele, TEM-1, in vitro and selected for cefepime resistance.	Cefepime	74-82	MFT2	Homo sapiens	25-28
15847220-14	2005	Comparison of drug-sensitivity to cephem by ESBL-gene type revealed that cefpirome, cefepime and cefozopran had higher MIC50/90 values against the CTX-M group with a MIC50 of greater than 128microg/ml.	Cefepime	84-92	EsbL	Escherichia coli	44-48
15150168-1	2004	OBJECTIVES: In this study, we evaluated the performance of a new ESBL Etest configuration based on clavulanate synergy with cefepime compared with cefotaxime-clavulanate and ceftazidime-clavulanate ESBL Etest strips for the detection of extended-spectrum beta-lactamases (ESBL) in an Enterobacteriaceae strain collection, with special focus on Enterobacter spp.	Cefepime	124-132	EsbL	Klebsiella oxytoca	65-69
15155182-0	2004	Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.	Cefepime	56-64	beta-lactamase	Escherichia coli	91-105
12730001-14	2003	Cefepime remained highly active, even against ceftazidime-resistant isolates of Enterobacter spp.	Cefepime	0-8	histocompatibility minor 13	Homo sapiens	93-96
12482126-3	2002	The aim of this study was to prospectively evaluate the effectiveness of cefepime monotherapy in the treatment of cancer patients with febrile granulocytopenia (< 1000 leukocytes/muL and/or < 500 neutrophils/muL).	Cefepime	73-81	tripartite motif containing 37	Homo sapiens	182-185
12615876-4	2003	Detection of KPC-2 may be a problem for clinical laboratories because in this study it was associated with positive extended-spectrum beta-lactamase (ESBL) confirmation tests (clavulanate-potentiated activities of ceftriaxone, ceftazidime, cefepime and aztreonam).	Cefepime	240-248	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	13-18
12574281-7	2003	In vitro susceptibility testing with standard inocula showed that all five AmpC-producing strains were susceptible to cefepime, imipenem, and ertapenem but that with a high inoculum, more of these strains were susceptible to the carbapenems than to cefepime.	Cefepime	118-126	beta-lactamase	Klebsiella pneumoniae	75-79
12574281-7	2003	In vitro susceptibility testing with standard inocula showed that all five AmpC-producing strains were susceptible to cefepime, imipenem, and ertapenem but that with a high inoculum, more of these strains were susceptible to the carbapenems than to cefepime.	Cefepime	249-257	beta-lactamase	Klebsiella pneumoniae	75-79
12574281-8	2003	All but 1 of 14 screen-positive AmpC nonproducers (and ESBL nonproducers) were susceptible to ceftriaxone and cefepime at the standard inoculum as were 6 of 6 isolates that were randomly selected and tested with a high inoculum.	Cefepime	110-118	beta-lactamase	Klebsiella pneumoniae	32-36
14628571-6	2003	The same was confirmed by the prospective and retrospective investigations of a multiprofile hospital on the clinical and bacteriological efficacies of the 3rd generation cephalosporins and cefepime in the treatment of hospital-acquired infections due to Enterobacteriaceae strains producing ESBL.	Cefepime	190-198	EsbL	Escherichia coli	292-296
12507831-0	2003	Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp.	Cefepime	92-100	histocompatibility minor 13	Homo sapiens	123-126
12507831-13	2003	Carbapenems (imipenem, meropenem) and cefepime had excellent activity against both ceftazidime-susceptible and -resistant Enterobacter spp.	Cefepime	38-46	histocompatibility minor 13	Homo sapiens	135-138
11996691-0	2002	Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.	Cefepime	0-8	beta-lactamase	Klebsiella pneumoniae	53-67
12482126-3	2002	The aim of this study was to prospectively evaluate the effectiveness of cefepime monotherapy in the treatment of cancer patients with febrile granulocytopenia (< 1000 leukocytes/muL and/or < 500 neutrophils/muL).	Cefepime	73-81	tripartite motif containing 37	Homo sapiens	214-217
10636865-5	2000	The beta-lactam antibiotics cephaloridine, cefoselis, cefepime, and cefluprenam were found to inhibit OCTN2-mediated carnitine transport.	Cefepime	54-62	solute carrier family 22 member 5	Homo sapiens	102-107
10854806-6	2000	Cefepime was the most active agent tested against pathogens with the potential for enzyme-mediated resistance due to Amp C.	Cefepime	0-8	beta-lactamase	Escherichia coli	117-122
10722487-8	2000	VIM-2 conferred a resistance pattern to beta-lactams in E. coli DH10B that paralleled its in vitro hydrolytic properties, except for susceptibility to ureidopenicillins, carbapenems, and cefepime.	Cefepime	187-195	VIM-2	Pseudomonas aeruginosa	0-5
10636865-10	2000	In contrast, cephaloridine, cefoselis, cefepime, and cefluprenam, which were recognized by OCTN2, did not interact with PEPT1 and PEPT2.	Cefepime	39-47	solute carrier family 22 member 5	Homo sapiens	91-96
10636865-11	2000	The interaction of cephaloridine with OCTN2 was Na(+)-dependent, whereas the interaction of cefoselis and cefepime with OCTN2 was largely Na(+)-independent.	Cefepime	106-114	solute carrier family 22 member 5	Homo sapiens	120-125
11105137-8	1997	Ciprofloxacin (MIC90, 1microg/mL, 94% susceptibility) and cefepime (MIC90, 6microg/mL, 92% susceptibility), were also very active against our collection of ESBL producing K pneumoniae.	Cefepime	58-66	CTX-M-15	Klebsiella pneumoniae	156-160
10668589-8	1999	Cefepime was more active against these two species as well as against Amp C producing species, indole-positive Proteae, and Acinetobacter species.	Cefepime	0-8	beta-lactamase	Escherichia coli	70-75
10052697-2	1999	Cefepime and the internal standard cefadroxil were separated on a Shandon Hypersil BDS C18 column by using a mobile phase of 25 mM sodium dihydrogen phosphate monohydrate (pH 3) and methanol (87:13, v/v).	Cefepime	0-8	Bardet-Biedl syndrome 9	Homo sapiens	87-90
11105137-11	1997	Cefotetan and cefepime were also very active against ESBL producing K.pneumoniaein Brazil; however, further studies are necessary to evaluate the role of these cephalosporins in the treatment of infections due to ESBL producing strains.	Cefepime	14-22	CTX-M-15	Klebsiella pneumoniae	213-217
11105137-11	1997	Cefotetan and cefepime were also very active against ESBL producing K.pneumoniaein Brazil; however, further studies are necessary to evaluate the role of these cephalosporins in the treatment of infections due to ESBL producing strains.	Cefepime	14-22	CTX-M-15	Klebsiella pneumoniae	53-57
1424521-2	1992	In general, both cefprozil and cefepime MICs were higher for beta-lactamase-producing strains of M. catarrhalis in comparison to strains that lacked beta-lactamase.	Cefepime	31-39	beta-lactamase TEM-1	Haemophilus influenzae	61-75
8738850-3	1996	Experimental studies have shown that cefepime and cefpirome penetrated remarkably well into the CSF of animals infected with Streptococcus pneumoniae, Streptococcus agalactiae, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae type b or Pseudomonas aeruginosa.	Cefepime	37-45	colony stimulating factor 2	Homo sapiens	96-99
8738850-4	1996	The mean changes in bacterial colony count in CSF after cefpirome or cefepime administration express the antibacterial activity of these drugs.	Cefepime	69-77	colony stimulating factor 2	Homo sapiens	46-49
8738850-5	1996	Studies in patients show that cefepime and cefpirome crossed the blood-brain barrier and reached concentrations in the CSF that are bactericidal against most potential pathogens.	Cefepime	30-38	colony stimulating factor 2	Homo sapiens	119-122
8150770-13	1993	Gentamicin, tobramycin, imipenem, ciprofloxacin, cefepime, and cefpirome were consistently active against most isolates of Enterobacter spp.	Cefepime	49-57	histocompatibility minor 13	Homo sapiens	136-139
1424521-3	1992	By contrast, beta-lactamase-positive and -negative strains of H. influenzae had similar cefprozil and cefepime minimum inhibitory concentrations (MICs).	Cefepime	102-110	beta-lactamase TEM-1	Haemophilus influenzae	13-27
1424521-6	1992	The cefepime MIC values against S. pneumoniae, H. influenzae, and beta-lactamase-positive and negative strains of M. catarrhalis were 0.03, 0.25, 2.0, and 0.5 micrograms/ml, respectively.	Cefepime	4-12	beta-lactamase TEM-1	Haemophilus influenzae	66-80
34902271-9	2022	For OID, cefepime 0.5-1g 4-hour infusion q8-24hr with CrCl<70 mL/min was needed to achieve a target range of free trough:MIC 1-4 at MIC 8 mg/L, while continuous infusion was needed for higher CrCl and weight values.	Cefepime	9-17	coiled-coil-helix-coiled-coil-helix domain containing 5	Homo sapiens	121-128
34808572-4	2022	The structures of the polymerized impurities in cefotaxime sodium and cefepime were deduced based on the MSn data, six of which were previously unknown.	Cefepime	70-78	moesin	Homo sapiens	105-108
34688834-0	2021	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).	Cefepime	31-39	microtubule associated protein 9	Homo sapiens	117-121
34807754-9	2022	Cefepime/enmetazobactam displayed the lowest activity (MIC50/90 1/>=128 mg/L), with MICs >=16 mg/L for 49 MBL producers, 40 OXA-48 producers (13 with amino acid changes in OmpK35/36, 4 in PBPs and 11 in RamR) and 25 KPC producers (most with an insertion in OmpK36).	Cefepime	0-8	mannose-binding lectin family member 3, pseudogene	Homo sapiens	106-109
34827216-14	2021	Both ceftazidime and cefepime showed very good inhibitory activity towards SARS CoV-2"s Mpro, with IC50 values of 1.81 microM and 8.53 microM, respectively.	Cefepime	21-29	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	88-92
34137456-8	2021	The model-based CrCL estimates were superior to standard approaches to estimate CrCL (or glomerular filtration rate) including Cockcroft-Gault, mCrCL, four-variable modification of diet in renal disease (MDRD), six-variable MDRD and chronic kidney disease epidemiology collaboration (CKD-EPI) as a covariate to describe cefepime and meropenem pharmacokinetics in terms of objective function value.	Cefepime	320-328	CRCL	Homo sapiens	16-20
34430873-10	2021	Conclusions: Hyperproduction of chromosomal AmpC appears to be the most common mechanism of resistance to ceftazidime and/or cefepime in E. cloacae and C. freundii.	Cefepime	125-133	beta lactamase DHA-1	Citrobacter freundii	44-48
34747449-8	2022	The efficacy of cefepime HSR and cefepime/taniborbactam HSR was determined as the change in log10 cfu/kidney at 48 h compared with 48 h controls.	Cefepime	16-24	component of Sp100-rs	Mus musculus	25-28
34249771-1	2021	AmpC beta-lactamases hydrolyze all beta-lactams except cefepime and carbapenems.	Cefepime	55-63	beta-lactamase	Escherichia coli	0-4
34161207-7	2022	Among 936 (93.6%) ESBL producing bacteria, 614 (61.4 %) E. coli showedhigh resistance to the antibiotics, Cefotaxime (85.7 %), Cefepime (85.7 %), Ciprofloxacin (83.1 %) and Kanamycin (77.9 %).	Cefepime	127-135	EsbL	Escherichia coli	18-22
34094864-3	2021	We report the first documented case of EP secondary to cefepime for the treatment of pneumonia.	Cefepime	55-63	epiregulin	Homo sapiens	39-41
35563520-0	2022	Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents.	Cefepime	40-48	CD274 antigen	Mus musculus	20-24
35563520-4	2022	Among the candidates, we identified the beta-lactam cephalosporin antibiotic cefepime as a tumor PDL1-depleting drug (PDD) that increases tumor DNA damage and sensitivity to DNA-damaging agents in vitro in distinct aggressive mouse and human cancer lines, including glioblastoma multiforme, ovarian cancer, bladder cancer, and melanoma.	Cefepime	77-85	CD274 antigen	Mus musculus	97-101
35563520-5	2022	Cefepime reduced tumor PDL1 post-translationally through ubiquitination, improved DNA-damaging-agent treatment efficacy in vivo in immune-deficient and -proficient mice, activated immunogenic tumor STING signals, and phenocopied specific genetic PDL1 depletion effects.	Cefepime	0-8	CD274 antigen	Mus musculus	23-27
35563520-5	2022	Cefepime reduced tumor PDL1 post-translationally through ubiquitination, improved DNA-damaging-agent treatment efficacy in vivo in immune-deficient and -proficient mice, activated immunogenic tumor STING signals, and phenocopied specific genetic PDL1 depletion effects.	Cefepime	0-8	CD274 antigen	Mus musculus	246-250
34747449-9	2022	RESULTS: Mean +- SD initial bacterial burden was 5.66 +- 0.56 log10 cfu/kidney, which increased to 9.05 +- 0.39 log10 cfu/kidney at 48 h. The cefepime HSR was ineffective, as bacterial burden was similar to untreated controls (-0.14 +- 0.40 change in log10 cfu/kidney).	Cefepime	142-150	component of Sp100-rs	Mus musculus	151-154
35368056-5	2022	RESULTS: MICs of zidebactam, tested alone, were strongly inoculum dependent regardless of beta-lactamase type; MICs of its cefepime and ertapenem combinations likewise were strongly inoculum dependent-rising >=32-fold across the inoculum range tested-but only for MBL producers.	Cefepime	123-131	mannose-binding lectin family member 3, pseudogene	Homo sapiens	264-267
33139291-5	2020	Cefepime-zidebactam showed MIC <=2mg/L for 92.0% (196/213) of bla KPC-2-producers and 79.7% (47/59) of bla NDM-producers.	Cefepime	0-8	Beta lactamase	Pseudomonas aeruginosa	62-65
2499250-0	1989	Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.	Cefepime	12-20	Beta lactamase	Pseudomonas aeruginosa	114-128
2499250-6	1989	Cefepime-resistant P. aeruginosa strains had exceptionally high levels of beta-lactamase activity, higher than the levels found in strains resistant to ceftazidime but susceptible to cefepime.	Cefepime	0-8	Beta lactamase	Pseudomonas aeruginosa	74-88
2499250-8	1989	Thus, cefepime was active against most gram-negative bacteria which have developed resistance to the broad-spectrum cephalosporins, and resistance to cefepime in P. aeruginosa appears to be associated with higher beta-lactamase levels than in cefepime-susceptible strains.	Cefepime	6-14	Beta lactamase	Pseudomonas aeruginosa	213-227
2499250-8	1989	Thus, cefepime was active against most gram-negative bacteria which have developed resistance to the broad-spectrum cephalosporins, and resistance to cefepime in P. aeruginosa appears to be associated with higher beta-lactamase levels than in cefepime-susceptible strains.	Cefepime	150-158	Beta lactamase	Pseudomonas aeruginosa	213-227
2499250-8	1989	Thus, cefepime was active against most gram-negative bacteria which have developed resistance to the broad-spectrum cephalosporins, and resistance to cefepime in P. aeruginosa appears to be associated with higher beta-lactamase levels than in cefepime-susceptible strains.	Cefepime	150-158	Beta lactamase	Pseudomonas aeruginosa	213-227
33179050-2	2021	In the current study, we examined the in vivo activity of a cefepime human-simulated regimen against MBL-producing Enterobacterales in a murine thigh infection model.	Cefepime	60-68	mannose-binding lectin family member 3, pseudogene	Homo sapiens	101-104
33179050-8	2021	RESULTS: MBL-producing Enterobacterales strains were found to be cefepime, piperacillin/tazobactam and meropenem non-susceptible in conventional broth.	Cefepime	65-73	mannose-binding lectin (protein C) 2	Mus musculus	9-12
33179050-10	2021	In accordance with the MICs generated in zinc-limited broth, administration of a cefepime human-simulated regimen was associated with substantial bacterial reductions among mice infected with MBL-producing Enterobacterales.	Cefepime	81-89	mannose-binding lectin (protein C) 2	Mus musculus	192-195
33139291-5	2020	Cefepime-zidebactam showed MIC <=2mg/L for 92.0% (196/213) of bla KPC-2-producers and 79.7% (47/59) of bla NDM-producers.	Cefepime	0-8	KPC-2	Pseudomonas aeruginosa	66-71
33139291-5	2020	Cefepime-zidebactam showed MIC <=2mg/L for 92.0% (196/213) of bla KPC-2-producers and 79.7% (47/59) of bla NDM-producers.	Cefepime	0-8	Beta lactamase	Pseudomonas aeruginosa	103-106
33139291-10	2020	Cefepime-zidebactam was highly active against clinical isolates of Enterobacterales and P. aeruginosa, including bla KPC-2-positive Enterobacterales and bla NDM-positive Enterobacterales and carbapenem-resistant P. aeruginosa And ceftazidime-avibactam was highly active against bla KPC-2-positive Enterobacterales and carbapenem-resistant P. aeruginosa.	Cefepime	0-8	Beta lactamase	Pseudomonas aeruginosa	113-116
33139291-10	2020	Cefepime-zidebactam was highly active against clinical isolates of Enterobacterales and P. aeruginosa, including bla KPC-2-positive Enterobacterales and bla NDM-positive Enterobacterales and carbapenem-resistant P. aeruginosa And ceftazidime-avibactam was highly active against bla KPC-2-positive Enterobacterales and carbapenem-resistant P. aeruginosa.	Cefepime	0-8	KPC-2	Pseudomonas aeruginosa	117-122
33139291-10	2020	Cefepime-zidebactam was highly active against clinical isolates of Enterobacterales and P. aeruginosa, including bla KPC-2-positive Enterobacterales and bla NDM-positive Enterobacterales and carbapenem-resistant P. aeruginosa And ceftazidime-avibactam was highly active against bla KPC-2-positive Enterobacterales and carbapenem-resistant P. aeruginosa.	Cefepime	0-8	Beta lactamase	Pseudomonas aeruginosa	153-156
33139291-10	2020	Cefepime-zidebactam was highly active against clinical isolates of Enterobacterales and P. aeruginosa, including bla KPC-2-positive Enterobacterales and bla NDM-positive Enterobacterales and carbapenem-resistant P. aeruginosa And ceftazidime-avibactam was highly active against bla KPC-2-positive Enterobacterales and carbapenem-resistant P. aeruginosa.	Cefepime	0-8	Beta lactamase	Pseudomonas aeruginosa	153-156
33139291-10	2020	Cefepime-zidebactam was highly active against clinical isolates of Enterobacterales and P. aeruginosa, including bla KPC-2-positive Enterobacterales and bla NDM-positive Enterobacterales and carbapenem-resistant P. aeruginosa And ceftazidime-avibactam was highly active against bla KPC-2-positive Enterobacterales and carbapenem-resistant P. aeruginosa.	Cefepime	0-8	KPC-2	Pseudomonas aeruginosa	282-287
32459878-5	2020	All of the compounds show very good inhibition of KPC2, with Kis ranging from 1 nM to 1 microM and most of them are able to restore cefepime activity against Klebsiella pneumoniae harboring blaKPC-2.	Cefepime	132-140	carbapenem-hydrolyzing beta-lactamase KPC-2	Klebsiella pneumoniae	50-54
32840000-4	2020	In addition to TtgABC, mutants of the second type such as HPG-5 were found to upregulate a novel RND pump, dubbed ParXY/TtgC, which accommodates cefepim, fluoroquinolones and aminoglycosides.	Cefepime	145-152	adeC/adeK/oprM family multidrug efflux complex outer membrane factor	Pseudomonas putida KT2440	120-124
33140656-3	2020	Other agents showing in vitro activity against MBL-GNB are currently in clinical development (e.g., cefepime/taniborbactam, LYS228, cefepime/zidebactam) that could be an important addition to our future armamentarium for severe MBL-GNB infections.	Cefepime	100-109	mannose-binding lectin family member 3, pseudogene	Homo sapiens	47-50
32572550-11	2020	The findings of this study displayed that cefepime + sulbactam combination had synergistic or additive effect against OXA-48-producing K. pneumoniae strains.	Cefepime	42-50	OXA-48	Klebsiella pneumoniae	118-124
32572550-13	2020	Further investigations may be helpful for understanding the effectiveness of cefepime + sulbactam combinations for OXA-48-positive carbapenem-resistant K. pneumoniae isolates.	Cefepime	77-85	OXA-48	Klebsiella pneumoniae	115-121
32872649-0	2020	Efficacy and Safety of Cystatin C-Guided Renal Dose Adjustment of Cefepime Treatment in Hospitalized Patients with Pneumonia.	Cefepime	66-74	cystatin C	Homo sapiens	23-33
32872649-3	2020	We investigated the efficacy and safety of CysC-guided cefepime dosing compared with SCr-guided dosing in hospitalized patients with pneumonia.	Cefepime	55-63	cystatin C	Homo sapiens	43-47
32872649-6	2020	One hundred and ninety patients were divided into two groups: 129 and 61 received cefepime based on CysC and SCr, respectively.	Cefepime	82-90	cystatin C	Homo sapiens	100-104
32872649-8	2020	CysC-guided cefepime dosing decreased the risk of AKI (13% versus 61%; HR 0.18; 95% CI, 0.07-0.44; p < 0.001) and CIE (2% versus 11%; HR 0.11; 95% CI, 0.03-0.47; p = 0.003) compared with SCr-guided dosing.	Cefepime	12-20	cystatin C	Homo sapiens	0-4
32872649-10	2020	CysC-guided dosing of cefepime was associated with decreased risk of the cefepime-associated morbidities including AKI and CIE without increasing mortality among the hospitalized patients with pneumonia.	Cefepime	22-30	cystatin C	Homo sapiens	0-4
32872649-10	2020	CysC-guided dosing of cefepime was associated with decreased risk of the cefepime-associated morbidities including AKI and CIE without increasing mortality among the hospitalized patients with pneumonia.	Cefepime	73-81	cystatin C	Homo sapiens	0-4
32459878-5	2020	All of the compounds show very good inhibition of KPC2, with Kis ranging from 1 nM to 1 microM and most of them are able to restore cefepime activity against Klebsiella pneumoniae harboring blaKPC-2.	Cefepime	132-140	KPC-2 protein	Klebsiella pneumoniae	190-198
31244817-0	2019	Gradual in vitro Evolution of Cefepime Resistance in an ST131 Escherichia coli Strain Expressing a Plasmid-Encoded CMY-2 beta-Lactamase.	Cefepime	30-38	CMY-2 beta-lactamase	Escherichia coli	115-135
32083659-4	2020	METHODS: Pseudomonal PBP-binding affinities of cefepime, zidebactam and imipenem were assessed at different timepoints and also in the presence of purified VIM-1 using a Bocillin FL competition assay.	Cefepime	47-55	dedicator of cyto-kinesis 3	Mus musculus	21-24
32083659-9	2020	Finally, complementary PBP inhibition by cefepime/zidebactam resulted in enhanced bactericidal activity in time-kill and neutropenic mouse lung/thigh infection studies against VIM-6-, VIM-10- and VIM-11-expressing P. aeruginosa, thus revealing the mechanistic basis of beta-lactam enhancer action.	Cefepime	41-49	dedicator of cyto-kinesis 3	Mus musculus	23-26
32083659-11	2020	For cefepime, this seems to be a result of a faster rate of PBP binding, which helps it overcome beta-lactamase-mediated hydrolysis.	Cefepime	4-12	dedicator of cyto-kinesis 3	Mus musculus	60-63
32477310-13	2020	The present study demonstrated that the bla CTX-M-55 gene mobilized by ISEcp1- bla CTX-M-55-ORF477 was the main feature shared by CRSE isolates and seems to play an important role for transmission of cefepime resistance.	Cefepime	200-208	TEM beta-lactamase	Klebsiella pneumoniae	40-43
32477310-13	2020	The present study demonstrated that the bla CTX-M-55 gene mobilized by ISEcp1- bla CTX-M-55-ORF477 was the main feature shared by CRSE isolates and seems to play an important role for transmission of cefepime resistance.	Cefepime	200-208	TEM beta-lactamase	Klebsiella pneumoniae	79-82
32477310-14	2020	The number of CRSE isolates is rising annually, and the strong dissemination ability of ISEcp1-bla CTX-M-55-ORF477-harboring plasmids among different species represents an important threat to the therapeutic effectiveness of cefepime.	Cefepime	225-233	TEM beta-lactamase	Klebsiella pneumoniae	95-98
31591114-3	2019	In the current study, we evaluated the effect of zidebactam on the cefepime pharmacodynamic target time above MIC (T>MIC) exposure required for efficacy against a diverse group of carbapenem-resistant Enterobacteriaceae (CRE) secondary to MBL-production.	Cefepime	67-75	mannose-binding lectin (protein C) 2	Mus musculus	239-242
31201049-5	2019	Eleven patients at our hospital were identified with CRN (9 cefepime, 2 ceftriaxone): all had an encephalopathy with decreased consciousness and/or confusion.	Cefepime	60-68	corin, serine peptidase	Homo sapiens	53-56
32742595-9	2020	Existence of bla IMP conferred more resistance to cephalotin, fosfomycin, and piperacillin (P<=0.01) and carrying bla VIM caused more resistance to cephalotin, cefepime, and ceftazidime (P<=0.01).	Cefepime	160-168	vimentin	Homo sapiens	118-121
31954597-4	2020	82.4% of isolates of ESBL-positive, carbapenemase-negative Enterobacteriaceae were susceptible to ceftolozane/tazobactam, compared to 1.5%, 7.8%, 20.3%, 71.1%, 94.7%, and 98.7%, respectively, for ceftriaxone, cefepime, ceftazidime, piperacillin-tazobactam, ertapenem, and meropenem.	Cefepime	209-217	EsbL	Escherichia coli	21-25
31641765-1	2020	OBJECTIVES: WCK 5222 combines cefepime with zidebactam, a beta-lactam enhancer that binds PBP2 and inhibits class A and C beta-lactamases.	Cefepime	30-38	phosphatidylethanolamine binding protein 2	Mus musculus	90-94
26513341-9	2016	ESBL-producing strains found in the community were more likely to be susceptible to gentamicin, netilmicin, and cefepime than those found in hospital.	Cefepime	112-120	EsbL	Escherichia coli	0-4
30258039-8	2018	Lower MICs for ceftriaxone, cefepime, aztreonam, meropenem, and imipenem for the mutated KPC-2-producing isolates were observed compared to those of the isolates producing a wild-type KPC-2.	Cefepime	28-36	KPC-2	Escherichia coli	89-94
29709981-0	2018	Plasmid-Mediated AmpC beta-Lactamase and Underestimation of Extended-Spectrum beta-Lactamase in Cefepime-Susceptible Elevated-Ceftazidime-MIC Enterobacteriaceae Isolates.	Cefepime	96-104	EsbL	Escherichia coli	60-92
28848015-0	2017	Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-beta-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection.	Cefepime	49-57	EsbL	Escherichia coli	95-127
30375126-0	2019	Cefepime-induced encephalopathy: Neural mass modeling of triphasic wave-like generalized periodic discharges with a high negative component (Tri-HNC).	Cefepime	0-8	tRNA-Ile (anticodon AAT) 9-1	Homo sapiens	141-144
29260037-2	2017	This is a case-series of three patients who presented to our hospital with confusion secondary to cefepime use to treat urinary tract infection (UTI) and health care associated pneumonia (HCAP), after excluding other common etiologies of altered mental status (AMS).	Cefepime	98-106	structural maintenance of chromosomes 3	Homo sapiens	188-192
27441293-9	2016	CONCLUSION: Unlike previous observations with MBL-producing Enterobacteriaceae that showed discordance between in vitro resistance and in vivo efficacy in the murine infection model, we found that the efficacy of humanized cefepime and meropenem was generally concordant with the phenotypic profile of VIM-producing P. aeruginosa.	Cefepime	223-231	mannose-binding lectin (protein C) 2	Mus musculus	46-49
25793625-10	2015	The most important observation was the restoration of susceptibility of P. aeruginosa WUM226 to cefepime (MIC decrease from 32 to 4 mg/L) and ceftazidime (MIC decrease from 128 to 4 mg/L) in the presence of PAbetaN, which occurred despite an almost complete lack of beta-lactamase leakage from bacterial cells.	Cefepime	96-104	Beta lactamase	Pseudomonas aeruginosa	266-280
26891290-1	2016	Deposition of bioactive coatings composed of zinc oxide, cyclodextrin and cefepime (ZnO/CD/Cfp) was performed by the Matrix Assisted Pulsed Laser Evaporation (MAPLE) technique.	Cefepime	74-82	complement factor properdin	Homo sapiens	91-94
26891290-3	2016	The efficient release of cefepime was correlated with an increased anti-biofilm activity of ZnO/CD/Cfp composites.	Cefepime	25-33	complement factor properdin	Homo sapiens	99-102
25915520-6	2015	VIM-24 (R228L) confers enhanced resistance to cephems and increases the rate of turnover compared to that of VIM-2 (kcat/KM increased by 6- and 10-fold for ceftazidime and cefepime, respectively).	Cefepime	172-180	VIM-2	Pseudomonas aeruginosa	0-5
25600890-8	2015	Cefotaxime and cefepime showed very low activities against ESBL-producing isolates, with susceptibility rates of 0-0.8% and 1.0-13.6%, respectively.	Cefepime	15-23	EsbL	Escherichia coli	59-63
26295796-0	2016	Reduced Susceptibility to Cefepime in Clinical Isolates of Enterobacteriaceae Producing OXA-1 Beta-Lactamase.	Cefepime	26-34	beta-lactamase OXA-1 precursor	Escherichia coli	88-93
25398058-9	2015	Although 52.4% and 66.7% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam and cefepime, respectively, 96.7% of all the isolates and 90.5% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam or cefepime in combination with aminoglycoside.	Cefepime	104-112	EsbL	Escherichia coli	32-36
25398058-9	2015	Although 52.4% and 66.7% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam and cefepime, respectively, 96.7% of all the isolates and 90.5% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam or cefepime in combination with aminoglycoside.	Cefepime	104-112	EsbL	Escherichia coli	171-175
25398058-9	2015	Although 52.4% and 66.7% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam and cefepime, respectively, 96.7% of all the isolates and 90.5% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam or cefepime in combination with aminoglycoside.	Cefepime	242-250	EsbL	Escherichia coli	32-36
25398058-10	2015	In conclusion, the ESBL group did not show a significantly unfavorable outcome, and empirical therapy with piperacillin/tazobactam or cefepime in combination with aminoglycoside might be more useful for febrile neutropenic children, instead of beta-lactam monotherapy in institutions with high prevalence of ESBL-producing E. coli and K. pneumoniae.	Cefepime	134-142	EsbL	Escherichia coli	308-312
24752253-0	2014	Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-beta-lactamase-producing Escherichia coli.	Cefepime	52-60	beta-lactamase	Escherichia coli	97-111
23973410-4	2015	The double-disk synergy test using disks containing cefepime (30 mug) with or without clavulanate (10 mug) was applied to confirm production of ESBL for isolates with cephalosporin MIC &gt;= 2 mug/mL.	Cefepime	52-60	EsbL	Escherichia coli	144-148
23973410-6	2015	The rates of cefepime susceptibility among the ESBL-producing isolates, according to CLSI (EUCAST) criteria, were 56.7% (22.4%) for E. coli, 61.3% (12.0%) for K. pneumoniae, 57.9% (31.6%) for E. cloacae, and 71.4% (7.1%) for P. mirabilis.	Cefepime	13-21	EsbL	Escherichia coli	47-51
23973410-8	2015	In addition, we also found that the cefepime MIC level of 1.0 mug/mL best distinguished non-ESBL- from ESBL-producing K. pneumoniae and E. cloacae.	Cefepime	36-44	EsbL	Escherichia coli	92-96
23973410-8	2015	In addition, we also found that the cefepime MIC level of 1.0 mug/mL best distinguished non-ESBL- from ESBL-producing K. pneumoniae and E. cloacae.	Cefepime	36-44	EsbL	Escherichia coli	103-107
24777102-1	2014	Mox-1 is a unique plasmid-mediated class C beta-lactamase that hydrolyzes penicillins, cephalothin, and the expanded-spectrum cephalosporins cefepime and moxalactam.	Cefepime	141-149	mesenchyme homeobox 1	Homo sapiens	0-5
24502096-10	2013	All ESBL isolates were susceptible to imipenem and resistant to ampicillin, piperacillin, cefazolin, cefotaxime, ceftazidime and cefepime.	Cefepime	129-137	EsbL	Escherichia coli	4-8
23671215-10	2013	CONCLUSIONS: A substantial portion of ESBL-producing isolates were susceptible to cefepime and ceftazidime by using the CLSI and EUCAST breakpoints.	Cefepime	82-90	EsbL	Escherichia coli	38-42
23529866-18	2013	Ceftriaxone, cefotaxime, ceftazidime, cefixime and cefepime have been studied in children and are all able to adequately penetrate the CSF.	Cefepime	51-59	colony stimulating factor 2	Homo sapiens	135-138
23413710-4	2012	Nearly all isolates non-susceptible to ceftriaxone, ceftazidime and cefepime produced ESBL; the presence of CTX-M genes in the isolates correlated with a ceftriaxone non-susceptible phenotype.	Cefepime	68-76	EsbL	Escherichia coli	86-90
23543257-9	2013	These strains were further tested for AmpC co-production by the AmpC disc test and all these strains were found to be AmpC positive, thus revealing the superior activity of cefepime in detecting ESBLs in the bacteria which co-produced AmpC.	Cefepime	173-181	beta-lactamase	Escherichia coli	38-42
23543257-9	2013	These strains were further tested for AmpC co-production by the AmpC disc test and all these strains were found to be AmpC positive, thus revealing the superior activity of cefepime in detecting ESBLs in the bacteria which co-produced AmpC.	Cefepime	173-181	beta-lactamase	Escherichia coli	64-68
23543257-9	2013	These strains were further tested for AmpC co-production by the AmpC disc test and all these strains were found to be AmpC positive, thus revealing the superior activity of cefepime in detecting ESBLs in the bacteria which co-produced AmpC.	Cefepime	173-181	beta-lactamase	Escherichia coli	64-68
23543257-9	2013	These strains were further tested for AmpC co-production by the AmpC disc test and all these strains were found to be AmpC positive, thus revealing the superior activity of cefepime in detecting ESBLs in the bacteria which co-produced AmpC.	Cefepime	173-181	beta-lactamase	Escherichia coli	64-68
23413710-5	2012	Thirty-nine of 83 isolates (47%) of ceftazidime-susceptible E. coli and 50 of 99 isolates (50.5%) of cefepime-susceptible E. coli were ESBL-producing.	Cefepime	101-109	EsbL	Escherichia coli	135-139